Straggler Novavax Still Hopes To Hit Paydirt With Combo Vaccine

 
• By Alaric DeArment

The company announced early data for a combination vaccine against SARS-CoV-2 and influenza, which could provide a revenue opportunity of $2bn.

Novavax Trial US
Novavax is aiming for a potentially $2bn opportunity with its SARS-CoV-2/influenza combination vaccine • Source: Getty Images

More from COVID-19

More from Scrip